Reasons to Add Immunovant Stocks (IMVT) to Your Portfolio Now – November 24, 2022

Reasons to Add Immunovant Stocks (IMVT) to Your Portfolio Now – November 24, 2022

Immunovant, Inc. (IMVT Quick QuoteIMVT – Free Report) currently looks like a good stock to invest in the biotech sector. Although smaller biotechs are riskier as their projects are several years away from commercialization, IMVT presents itself as a relatively safe but prospective option. Immunovat’s lead development candidate batoclimab (formerly IMVT-1401) is a fully human … Read more

Inhibrx (INBX) Inactive in Updated Bone Cancer Study Data – Nov 18, 2022

Inhibrx (INBX) Inactive in Updated Bone Cancer Study Data – Nov 18, 2022

inhibitx (INBX Quick QuoteINBX – Free report) reported updated safety and efficacy data from ongoing expansion cohorts of a phase I study evaluating INBRX-109 for chondrosarcoma. Inhibrx shares fell 11.52% on November 17 in response to the news, possibly because the observed study profit fell short of investor expectations. Image Source: Zacks Investment Research The … Read more

Immunovant (IMVT) Increases Over 150% in 3 Months: Here’s How – Nov 17, 2022

Immunovant (IMVT) Increases Over 150% in 3 Months: Here’s How – Nov 17, 2022

Actions of Immunovant, Inc. (IMVT Quick QuoteIMVT – Free Report) have increased by 158.9% in the last three months compared to the industryincrease of 2.1%. The company has made good progress during this period with the development of its lead candidate, batoclimab (formerly IMVT-1401), which is being developed for the treatment of various autoimmune diseases. … Read more

TIVIC HEALTH SYSTEMS, INC. Management’s Discussion and Analysis of Financial Condition and Results of Operations (Form 10-Q)

TIVIC HEALTH SYSTEMS, INC.  Management’s Discussion and Analysis of Financial Condition and Results of Operations (Form 10-Q)

The following discussion and analysis of our financial condition and results of operations should be read together with the interim condensed financial statements and related notes included elsewhere in this Quarterly Report on Form 10­Q, as well as our audited financial statements and related notes as disclosed in our Annual Report on Form 10­K for … Read more

ZOMEDICA CORP. Discussion and analysis of management’s financial situation and results of operations. (Form 10-Q)

ZOMEDICA CORP.  Discussion and analysis of management’s financial situation and results of operations.  (Form 10-Q)

DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION MANAGEMENT AND RESULTS OF OPERATION The following discussion and analysis of our financial condition and results of operations should be read together with our consolidated financial statements and the related notes and the other financial information included elsewhere in this Report. This discussion contains forward-looking statements within the meaning … Read more

LUCIRA HEALTH, INC. Discussion and analysis of management’s financial situation and results of operations. (Form 10-Q)

LUCIRA HEALTH, INC.  Discussion and analysis of management’s financial situation and results of operations.  (Form 10-Q)

The unaudited condensed financial statements and this Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the financial statements and notes thereto for the year ended December 31, 2021 and the related Management’s Discussion and Analysis of Financial Condition and Results of Operations, both of which are … Read more

SONOMA PHARMACEUTICALS, INC. Management’s Discussion and Analysis of Financial Condition and Results of Operations (Form 10-Q)

SONOMA PHARMACEUTICALS, INC.  Management’s Discussion and Analysis of Financial Condition and Results of Operations (Form 10-Q)

The following discussion of our financial condition and results of operations should be read in conjunction with the condensed consolidated financial statements and notes to those statements included elsewhere in this Quarterly Report on Form 10-Q as of September 30, 2022 and our audited consolidated financial statements for the year ended March 31, 2022 included … Read more

REVELATION BIOSCIENCES, INC. Management’s Discussion and Analysis of Financial Condition and Results of Operations (Form 10-Q)

REVELATION BIOSCIENCES, INC.  Management’s Discussion and Analysis of Financial Condition and Results of Operations (Form 10-Q)

You should read the following discussion of our financial condition and results of operations in conjunction with our financial statements and the notes included elsewhere in the Form 10-Q. The following discussion contains forward-looking statements that involve certain risks and uncertainties. Our actual results could differ materially from those discussed in these statements. Factors that … Read more

RENOVACOR, INC. Discussion and Analysis of the Administration’s Financial Situation and Results of Operations. (Form 10-Q)

RENOVACOR, INC.  Discussion and Analysis of the Administration’s Financial Situation and Results of Operations.  (Form 10-Q)

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with: • Our unaudited condensed consolidated financial statements and accompanying notes included in Part I, Item 1 of this Quarterly Report on Form 10-Q; Y • Our financial statements and the accompanying notes thereto included in our … Read more

EAGLE PHARMACEUTICALS, INC. Management’s Discussion and Analysis of Financial Condition and Results of Operations (Form 10-Q)

EAGLE PHARMACEUTICALS, INC.  Management’s Discussion and Analysis of Financial Condition and Results of Operations (Form 10-Q)

The following information should be read in conjunction with our unaudited consolidated financial statements and the notes thereto included in this Quarterly Report on Form 10-Q, or the Quarterly Report, and the audited financial information and the notes thereto included in our Annual Report on Form 10-K, which was filed with the Securities and Exchange … Read more